Vietnam Ophthalmic Drugs Market to Grow with a CAGR of 9.45% through 2030
Expansion of healthcare
infrastructure and prevalence of chronic diseases is expected to drive the
Vietnam Ophthalmic Drugs Market growth in the forecast period, 2026-2030.
According to TechSci Research report, “Vietnam Ophthalmic
Drugs Market –– By Region, Competition, Forecast and Opportunities, 2030F”,
the Vietnam Ophthalmic Drugs Market stood at USD 478.32 Million in 2024 and is
expected to reach USD 824.18 Million by 2030 with a CAGR of 9.45% during the
forecast period.
The Vietnam
ophthalmic drugs market is experiencing significant growth, driven by an
increasing burden of eye diseases, improved healthcare infrastructure, and
greater awareness of eye health. As the country’s population continues to age,
there is a notable rise in chronic eye conditions, such as glaucoma,
age-related macular degeneration (AMD), diabetic retinopathy, and cataracts,
all of which require ongoing treatment and management. These conditions are
becoming more prevalent, particularly among the elderly, and are driving the
demand for ophthalmic drugs. Glaucoma, for example, remains one of the leading
causes of blindness in the country, particularly given the country’s aging
population and the lack of early diagnosis and treatment in some areas.
One of the main
factors contributing to the growth of the ophthalmic drugs market in Vietnam is
the increasing awareness about eye health. Over the past decade, there has been
a marked shift in public health campaigns aimed at educating the population about
the importance of regular eye exams and the potential risks of untreated eye
conditions. The Vietnamese government, alongside healthcare professionals and
non-governmental organizations, has been actively promoting eye health
awareness, particularly through screenings for common conditions like glaucoma
and diabetic retinopathy. As a result, more people are seeking eye care at
earlier stages, increasing the demand for both preventive treatments and drugs
to manage chronic eye conditions. The rising demand for eye care services is
particularly notable in urban areas such as Ho Chi Minh City and Hanoi, where
there are more specialized ophthalmic care centers. The demand for ophthalmic
drugs, especially in metropolitan areas, is supported by the availability of
advanced diagnostic tools and cutting-edge treatment options. These urban
centers serve as hubs for medical innovation, attracting both local and
international pharmaceutical companies to introduce new ophthalmic drugs and
therapies.
The treatment of
eye diseases in Vietnam is dominated by a range of pharmaceutical categories.
Anti-glaucoma drugs, including beta-blockers, prostaglandin analogs, carbonic
anhydrase inhibitors, and newer options like rho kinase inhibitors, are among
the most commonly used medications in the country due to the high prevalence of
glaucoma. These medications are prescribed for long-term use, ensuring steady
demand over time. Prostaglandin analogs, in particular, have gained significant
popularity because they effectively reduce intraocular pressure with fewer side
effects compared to older drug classes, thus improving patient adherence to
treatment. Anti-VEGF (vascular endothelial growth factor) drugs used to treat
retinal diseases like diabetic retinopathy and age-related macular degeneration
are also seeing increased demand. However, these therapies tend to be more
expensive, limiting their use to patients in more affluent areas or those who
can afford specialized treatment. Anti-inflammatory drugs, used primarily to
manage uveitis or post-operative inflammation, are also important in the market
but tend to be less widely used than anti-glaucoma drugs, which are required on
a more ongoing basis for chronic conditions.
Another factor
driving the ophthalmic drugs market in Vietnam is the expanding healthcare
infrastructure. Over recent years, Vietnam has made considerable investments in
the healthcare sector, with increased public and private sector partnerships,
improving access to quality healthcare across the country. The presence of
modern healthcare facilities in urban areas has boosted the availability of
specialized ophthalmic care, and more patients are seeking treatment for eye
conditions. The rise of private healthcare providers, which often offer faster
and more advanced care compared to public facilities, is contributing to the
growing market for ophthalmic drugs. These private clinics and hospitals
typically offer a wider range of ophthalmic medications, from over-the-counter
solutions to more expensive, prescription-only treatments, which further drives
demand.
However, despite
the positive growth trajectory, the ophthalmic drugs market in Vietnam faces
several challenges. Access to eye care in rural areas remains limited, as there
is a lack of specialized ophthalmic services and a shortage of trained
ophthalmologists in many regions outside of major cities. This results in late
diagnoses and treatment, which often leads to more severe complications, such
as vision loss, when patients finally seek care. The affordability of
ophthalmic drugs, particularly expensive treatments such as anti-VEGF
injections, is also a major concern. While there is a growing middle class in
Vietnam, large portions of the population still face financial barriers to
accessing high-quality medical care, which limits the overall market potential.
The high cost of advanced treatments can also deter patients from seeking
timely care, exacerbating the issue of late-stage diagnoses.
Another
significant issue is the prevalence of counterfeit and substandard ophthalmic
drugs, which pose a risk to patient safety and market integrity. The presence
of counterfeit drugs in the market can undermine patient trust in the
healthcare system and discourage the use of essential medications. Regulatory
authorities are working to address this challenge by tightening regulations and
enforcement, but the problem still persists in some areas, especially in rural
regions where access to genuine products is limited.
Despite these
challenges, the future of the ophthalmic drugs market in Vietnam looks
promising. The country's growing focus on improving healthcare access,
alongside an increasing awareness of eye health, is expected to drive further
market growth. As the demand for effective treatments for age-related diseases,
such as glaucoma and retinal disorders, continues to rise, pharmaceutical
companies are likely to invest more heavily in developing and distributing
ophthalmic drugs in Vietnam. The expansion of generic ophthalmic drugs, which
offer more affordable alternatives to branded medications, will also help
improve accessibility for a larger portion of the population.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Vietnam Ophthalmic Drugs Market”
The Vietnam Ophthalmic Drugs Market is segmented into drug
class, drug disease, route of administration, dosage type, regional
distribution, and company.
Based on dosage type, Eye Drops are currently
dominating the market. Eye drops have become the preferred and most widely used
formulation for the treatment of eye conditions due to their convenience, ease
of use, and rapid action. This delivery form is particularly suitable for
conditions such as glaucoma, dry eye, infections, and allergies, all of which
are prevalent in Vietnam. The market for eye drops is vast because they can
effectively deliver medications directly to the eye, providing localized
treatment with minimal systemic side effects. The availability of eye drops in
a wide range of therapeutic categories, from anti-glaucoma drugs and
anti-inflammatory treatments to lubricants and antibiotics, has made them a
go-to option for both patients and healthcare providers.
One of the main reasons eye drops dominate the
Vietnamese ophthalmic drugs market is their ease of use. Unlike gels,
ointments, or capsules, eye drops are generally simple to apply, requiring no
special skills or equipment. This is particularly important in a country like
Vietnam, where varying levels of healthcare literacy exist, especially in rural
areas. Patients can administer eye drops independently, making them more
accessible to the broader population. This convenience factor contributes
significantly to their widespread adoption, particularly for chronic conditions
such as glaucoma, which require long-term, consistent medication. Patients find
it easier to maintain a regular treatment regimen with eye drops, as they are
typically available in pre-measured, single-use doses that can be conveniently
carried around.
Based on region, Northern Vietnam is the second
dominating region, following Southern Vietnam. The capital city, Hanoi, along
with other key cities in the north, has seen steady growth in both the demand
for and availability of ophthalmic drugs. While the southern region,
particularly Ho Chi Minh City, is recognized as the commercial and healthcare
hub, Northern Vietnam plays a critical role due to its growing healthcare
infrastructure, an increasing number of specialized medical professionals, and
a rising focus on eye health.
One of the main drivers of the ophthalmic drugs market
in Northern Vietnam is the increasing prevalence of eye diseases, particularly
among the aging population. Like the rest of the country, Northern Vietnam is
witnessing a demographic shift with a growing elderly population, which is more
susceptible to conditions such as glaucoma, cataracts, and age-related macular
degeneration. As these diseases become more common, the demand for ophthalmic
medications, especially those related to glaucoma and retinal disorders, has
grown. Hanoi, being the political and administrative center of the country, is
home to a large number of healthcare institutions, hospitals, and specialized
eye care centers. This concentration of medical resources in Northern Vietnam
allows for better diagnosis and treatment of eye conditions, contributing to
the increasing use of ophthalmic drugs in the region. In addition to an aging
population, awareness of eye health is also rising in Northern Vietnam, partly
due to public health campaigns and educational initiatives. Government programs
and collaboration with local organizations have been working to increase
awareness about common eye diseases, the importance of early diagnosis, and the
availability of effective treatments. As more people in Northern Vietnam
recognize the importance of eye health, they are more likely to seek treatment,
driving the demand for ophthalmic drugs. For example, more individuals are now
opting for regular glaucoma screenings, which has led to an uptick in the use
of anti-glaucoma drugs, a major component of the ophthalmic drugs market.
Major companies
operating in the Vietnam Ophthalmic Drugs Market are:
- Bayer Vietnam Ltd.
- DHG Pharmaceutical Joint Stock Company
- Traphaco Joint Stock Company
- Pharmaceutical Corporation Ha Tay
- Domesco Medical Import Export Joint Stock Corporation
(DOMESCO)
- OPC Pharmaceutical Joint Stock Company
- Sanofi-Aventis Vietnam
- Mekophar Chemical and Pharmaceutical JSC
- Merck Vietnam Company Ltd.
- Pymepharco Joint Stock Company
Download Free Sample Report
Customers can
also request 10% free customization on this report
“The future of
the Vietnam ophthalmic drugs market looks promising, driven by factors such as
an aging population, increased awareness of eye health, and advancements in
ophthalmic treatments. The growing prevalence of chronic eye conditions like
glaucoma, diabetic retinopathy, and cataracts will continue to fuel demand for
effective medications. Technological innovations in drug delivery systems and
the introduction of new therapies, including anti-VEGF and gene therapies, are
expected to enhance treatment options and improve patient outcomes. The
expansion of healthcare infrastructure, particularly in rural areas, and the
rising middle class will make ophthalmic drugs more accessible. With increasing
government and private sector investments, the market is poised for sustained
growth, offering significant opportunities for both local and international
pharmaceutical companies to expand their presence in Vietnam.,” said Mr. Karan
Chechi, Research Director, TechSci Research, a research-based management
consulting firm.
“Vietnam
Ophthalmic Drugs Market By Drug Class (Anti-Allergy, Anti-VEGF agents,
Anti-inflammatory, Anti-glaucoma, Gene & Cell Therapy, and Others), By Drug
Disease (Dry Eye, Allergies, Glaucoma Infection, Retinal Disorders, Uveitis,
Others), By Route Of Administration (Topical, and Local Ocular), By Dosage Type
(Gels, Eye solutions & suspensions, Capsules & Tablets, Eye drops, and
Ointments), By
Region, Competition, Forecast and
Opportunities, 2020-2030F”, has evaluated
the future growth potential of Vietnam Ophthalmic Drugs Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision-makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Vietnam Ophthalmic Drugs Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com